Novartis, Eli Lilly marquee positive survival data for CDK 4/6 franchises — but can they actually beat Pfizer's blockbuster?
BARCELONA — A little more than a year after Pfizer’s big CDK 4/6 cancer drug blockbuster Ibrance failed to hit the mark in overall survival, two big rivals are knocking on their front door bearing data from two Phase III studies clearly showing that their rival treatments can significantly extend the lives of patients.
Research teams for both turned up at ESMO over the weekend with promising OS results in advanced breast cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.